Literature DB >> 18684220

Oestrogen promotes coronary angiogenesis even under normoxic conditions.

Mehdi Nematbakhsh1, Mehrzad Ghadesi, Marzieh Hosseinbalam, Majid Khazaei, Marjan Gharagozloo, Marjan Gharagozlo, Gholamreza Dashti, Parvin Rajabi, Shahram Rafieian.   

Abstract

Angiogenic therapy is one of the new treatments of ischaemic heart disease. Oestrogen has angiogenic properties under hypoxic condition, and if oestrogen also induces angiogenesis under normoxic condition, it could be used in combination with other angiogenic therapies in the treatment of ischaemic heart disease. In this study, we evaluated the angiogenic effect of high-dose oestrogen treatment in normoxic rat heart tissue. Fifty-two ovariectomized rats were randomized in oestrogen-treated and control groups. 17beta-oestradiol (1 mg/week) and normal saline (1 mg/week) were administered intramuscularly in the treatment and control groups for 2 months. After that, coronary capillary density and coronary vessel permeability were measured. The serum vascular endothelial growth factor (VEGF) level was also measured before and after the treatment. The results indicate that coronary capillary density (number of capillary per square millimetre) and coronary vessel permeability (fluorescence intensity) were significantly higher in the oestrogen-treated group than in the control group (628 +/- 26 per mm(2) versus 540 +/- 26 per mm(2); P < 0.05 and 207 +/- 10 versus 147 +/- 19 per gram tissue; P < 0.05). Oestrogen treatment increased serum VEGF level in the oestrogen-treated group compared to the control group (52 +/- 3 versus 33 +/- 6 pg/ml; P < 0.05), but interestingly VEGF was also increased in the control group after placebo treatment. It seems that high-dose oestrogen administration has angiogenic properties even in normoxic conditions. These angiogenic properties may result from oestrogen's direct effect on VEGF or other mechanisms, such as endothelial progenitor cell mobilization. Because of the broad effect of oestrogen on angiogenic growth factors and endothelial cells, more studies are required to clarify angiogenic properties of high-dose oestrogen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684220     DOI: 10.1111/j.1742-7843.2008.00286.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  5 in total

1.  Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension.

Authors:  Grayson L Baird; Thomas Walsh; Jason Aliotta; Melissa Allahua; Ruth Andrew; Ghada Bourjeily; Alexander S Brodsky; Nina Denver; Mark Dooner; Elizabeth O Harrington; James R Klinger; Margaret R MacLean; Christopher J Mullin; Mandy Pereira; Athena Poppas; Mary Whittenhall; Corey E Ventetuolo
Journal:  Ann Am Thorac Soc       Date:  2021-02

2.  The relationship between prostatic microvessel density and different concentrations of oestrogen/androgen in Sprague-Dawley rats.

Authors:  Bo Wang; Di Pan; Yong Ban; Zhaolin Sun; Ye Tian; Guangheng Luo
Journal:  Eur J Med Res       Date:  2022-06-07       Impact factor: 4.981

3.  Vitamin E, Vitamin C, or Losartan Is Not Nephroprotectant against Cisplatin-Induced Nephrotoxicity in Presence of Estrogen in Ovariectomized Rat Model.

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Fatemeh Eshraghi-Jazi; Farzaneh Ashrafi; Hamid Nasri; Ardeshir Talebi; Tahereh Safari; Maryam Haghighi; Azam Mansouri
Journal:  Int J Nephrol       Date:  2012-09-26

4.  Evidence against protective role of sex hormone estrogen in Cisplatin-induced nephrotoxicity in ovarectomized rat model.

Authors:  Zahra Pezeshki; Mehdi Nematbakhsh; Hamid Nasri; Ardeshir Talebi; Ali-Asghar Pilehvarian; Tahereh Safari; Fatemeh Eshraghi-Jazi; Maryam Haghighi; Farzaneh Ashrafi
Journal:  Toxicol Int       Date:  2013-01

5.  Effect of Short Hydration on Cisplatin-Induced Nephrotoxicity in Cancer Patients: A Retrospective Study.

Authors:  Farzaneh Ashrafi; Zeinab Ebrahimi; Mehdi Nematbakhsh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.